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ABSTRACT
Introduction: Methadone is an opioid, which is prescribed for the treatment and management of opioid 
addiction. Despite its frequent use, caution should be exercised as it has side effects. Assessment of the patient’s 
clinical condition may be influenced and exacerbated by respiratory side effects. Sleep apnea is one of the side 
effects, which are observed in patients, treated with methadone.
Aim: The aim of the study is to see if there are interactions between methadone treatment and sleep apnea and 
if so - to determine how much methadone affects sleep.
Materials and Methods: In this study, we examined 36 patients, addicted to drugs and treated with methadone. 
To compare the results we received, we used database articles from Medline, Cochrane Database of Systematic 
Reviews, Google Scholar, PubMed, Springer Link, Journals of Sleep Medicine and Anesthesia and Analgesia, as 
well as other non-indexed pages. 
Results: From the survey we established: 80.6% (29) of patients on methadone therapy have problems with 
sleep; 9 (25%) have insomnia; 38.9% (14) feel morning fatigue; 16.1% (13) experience daytime sleepiness and 36.1% 
have a change in mood; 19.4% (7) of respondents say that their sleep is short and 16.7% report snoring; 75% do not 
have problems with falling asleep and 30.6% wake up frequently during the night.
Conclusion: Our study found that the majority of drug addicts reported poor sleep quality. In the treatment 
of patients with sleep apnea as a result of opioids, collaboration between specialists, monitoring of patients and a 
combination of different types of sleep apnea treatment is extremely important. 
Keywords: opioids, methadone therapy, sleep apnea, central sleep apnea
INTRODUCTION
Opioid addiction is a disorder that poses a major 
challenge for treatment. Very often patients have co-
morbid conditions such as HIV, hepatitis and other 
chronic conditions (1). Such patients are treated in re-
habilitation programs. In recent years, there have in-
creasingly been developed programs for the monitor-
ing and treatment of opiate addicts. These programs 
use controlled products that also have side effects.
Methadone is an opioid, which is used to re-
lieve chronic pain, treat heroin addiction, and is pre-
scribed for the treatment and management of opi-
oid addiction. It reduces opioid dependence on illicit 
drugs. Despite its frequent use, caution should be ex-
ercised as it has side effects. Тhe side effects that are 
observed are: dizziness, drowsiness, vomiting, sweat-
ing, dry mouth and constipation; sleep apnea, аbnor-
mal heart rhythms, respiratory problems, euphoria, 
disorientation, anxiety, seizures and more (2,3,4). 
Sleep apnea is considered when breathing during 
sleep stops for 10 seconds or more with an index of 5 
times or more an hour. In these patients, sleep is rest-
less, interrupted by waking hours. There is daily hy-
persomnolence with repeated involuntary sleepiness. 
Assessment of the patient’s clinical condition may be 
influenced and exacerbated by respiratory side ef-
fects (5).
The patients we examined were addicted to hero-
in. This is a brain disease with mental and/or physi-
cal dependence. Taking this opioid drug is different 
- smoking, snuffing, oral and intravenous adminis-
tration (6).
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AIM
The aim is to see if there are interactions between 
methadone treatment and sleep apnea and if so - to 
determine how much methadone affects sleep.
MATERIALS AND METHODS
In this study, we examined 36 patients who were 
addicted to drugs and treated with methadone. The 
patients we tested had previous heroin addiction, 
some with additional polydrug abuse. To compare 
the results we received, we used database articles 
from Medline, Cochrane Database of Systematic Re-
views, Google Scholar, PubMed, Springer Link, Jour-
nals of Sleep mMedicine and Anesthesia and Analge-
sia, as well as other non-indexed pages. 
The own study was conducted among patients 
treated at St. Marina University Hospital, Varna in 
the Department of Psychiatry and Medical Psychol-
ogy, and was monitored on an outpatient basis at St. 
Marina Diagnostic and Consultative Center, Varna. 
They are all familiar with the purpose of the study 
and have given their written consent. 
RESULTS
All patients were treated for opioid addiction. 
The patients studied were 35.1±7.2 years of age 
(mean±SD). Their gender distribution is as follows: 
47% women (17) and 53% men (19). 
The answers we received can be summarized 
as follows (Table 1): On the question “Do you have 
problems with sleep” - almost 2/3 of drug addicts, i.e. 
80.6% (29) reported having such. Based on wheth-
er or not they have sleep problems, the patients an-
swered the following questions about what their 
complaints were: 9 (25%) patients reported having 
insomnia; 38.9% (14) experienced morning fatigue; 
47.2% (17) of the respondents said they were drowsy 
during the day and 36.1% of the respondents report-
ed a change in mood. In 19.4% (7), sleep was short 
and 16.7% reported snoring. 
To the question “Do you find it difficult to fall 
asleep?” 75% answered in the negative. Of the pa-
tients studied, those who wake up frequently during 
the night were 30.6% (11). 
DISCUSSION
Many studies have demonstrated the depres-
sogenic effect of opioid derivatives on respiration (7). 
This effect is dose-dependent with increasing meth-
adone dosage, especially if combined with cardi-
ac or respiratory pathology (8). Methadone, which 
is a morphine derivative, can cause central sleep ap-
nea syndrome. According to a study of Mintzer and 
Stitzer this is observed in 61% of opiate patients (9). 
Therefore, treating physicians should exercise ex-
treme caution with the combination of medicines 
and follow methadone replacement therapy. 
When patients have trouble sleeping or feel sleepy 
during the day, they should be tested for sleep apnea. 
The gold standard is the polysomnographic research. 
These patients should undergo regular clinical mon-
itoring, sleep monitoring and quality assessment of 
cognitive function throughout the day (5).
Worldwide studies show that opioids inhibit cen-
tral cholinergic and adenosynergic transmission, 
thereby disrupting the underlying mechanisms of 
sleep and wakefulness. (10,11,12,13,14). Thus, the 
REM stage of sleep is inhibited, leading to sleep dis-
turbance in general, drowsiness and hyperalgesia 
(15,16). These opioid effects may affect the severity 
of opioid-induced ventilatory impairment. The re-
lationship between opioids and sleep problems has 
been shown to be two-way - drug use leads to sleep 
Fig. 1. Gender distribution of examined patients
YES NO
Do you have a problem 
with sleep? 80.6% (29) 19.4% (7)
Do you suffer from 
insomnia? 25% (9) 75% (27)
Do you have morning 
fatigue? 38.9 % (14) 61.1% (22)
Do you feel sleepy 
during the day? 47.2% (17) 52.8% (19)
Do you have mood 
swings during the day? 36.1% (13) 63.9% (23)
Is your sleep short? 19.4% (7) 80.6% (29)
Do you snore? 16.7% (6) 83.3% (30)
Are you having a hard 
time falling asleep? 25% (9) 75% (27)
Do you often wake up in 
the evening? 52.8% (19) 47.2% (17)
Table 1. Responses to the survey
59
Christiana Madjova, Simeon Chokanov, Mario Milkov
disorders, and sleep problems occur when it comes to 
recurrent abuse (17).
In patients with sleep apnea induced by opioids, 
it is specific that daytime sleepiness, dizziness and 
impaired concentration are observed (18). World-
wide studies show that patients on methadone ther-
apy suffer from central sleep apnea (19). What is spe-
cific about it is that oxygen cannot be delivered be-
cause patients cannot breathe or breathe extremely 
infrequently during episodes. This type of apnea is 
more difficult to treat and requires exceptional co-
ordination between healthcare professionals and pa-
tient monitoring.
Our survey shows that patients treated with 
methadone have also sleep problems. Each of them 
complained about a different problem associated 
with sleep disorders. We found that 80.6% of patients 
suffer from some sleep problems. Patients reported 
restless sleep and waking. This occurs when breath-
ing stops and these short wakes are characteristic of 
central sleep apnea. In central sleep apnea, the brain 
does not send the correct signals to the muscles that 
control breathing. Sleep disorders affect the quality 
of life of patients. For more detailed and exact exam-
ination, the methadone treated patients need to be 
tested in a polysomnographic study.
Other symptoms observed in the studied patients 
were changes in mood, increased drowsiness, morn-
ing fatigue. All this is typical of sleep apnea. Through 
the inquiry we found that the symptoms varied. Each 
addict reported different symptoms. Generally, af-
ter opioid administration, patients have shallow and 
wrong breathing leading to hypercapnia and hypox-
ia. Daytime sleepiness, dizziness and impaired con-
centration observed in patients are typical of central 
sleep apnea. 
For the treatment of patients on methadone ther-
apy, a multidisciplinary approach is crucial because 
central sleep apnea is more challenging to treat. The 
diagnosis must be based on a polysomnograph-
ic study. Оn examination a reduced effort to inhale 
during an obstructive event and longer than expect-
ed breathing breaks are established (20). 
In order to prove that there is sleep apnea, there 
are 3 symptoms that can be present both individu-
ally and together. These are: 1) the breathing pattern 
- ataxia or irregularly; 2) interruption of breathing 
- apnea or hypopnea 3) gas exchange - hypoxia and 
hypercapnia. The morphology of central sleep ap-
nea may be different - irregular intervals with ataxic 
breathing or intermittent cluster breathing (21). 
In recent years, there has been a trend of change in 
the management of chronic pain associated with opi-
oid use. This is due to the fact that these patients very 
often suffer from unexplained sleep apnea. In these 
patients, unexplained mortality was observed, drug 
addicts have been found dead in their beds (22). This 
requires very rigorous monitoring of patients under-
going morphine therapy. In case of doubt about ac-
companying conditions and diseases a mandatory 
consultation with the relevant specialist is needed.
Тreatment of opioid-induced sleep apnea is ex-
tremely difficult. According to Javaheri, this is be-
cause in some patients both obstructive sleep ap-
nea and central sleep apnea are observed (22). Stud-
ies show that central sleep apnea is more challenging 
to treat because it is not always affected by contin-
uous positive airway pressure (CPAP). The presence 
of such complex sleep apnea may also occur during 
CPAP treatment. This is common in patients with se-
vere obstructive sleep apnea, those with systolic heart 
failure, atrial fibrillation, neuromuscular disorders 
or on opioids (22). 
For the treatment of central sleep apnea there are 
summarized recommendations. In the presence of 
central sleep apnea associated with congestive heart 
failure, the goal of CPAP therapy is to normalize the 
sleep apnea index. Night oxygen therapy is also ap-
plied to the same type of central sleep apnea. Adap-
tive servo-ventilation (ASV), which aims at normal-
izing the apnea-hypopnea index (AHI), can also be 
used. 
When treatment is not affected by CPAP, ASV, 
and oxygen therapies, BPAP therapy is administered 
by a spontaneous timed (ST) mode. The goal again is 
to normalize AHI. Acetazolamide and theophylline 
are used in some patients, but only with very good 
clinical monitoring and lack of results from other 
treatments. In the case of primary central sleep ap-
nea, treatment is restarted with PAP therapy. Acet-
azolamide, zolpidem and triazolam may be consid-
ered in some cases, but in the absence of risk factors 
for respiratory depression (23). 
In patients receiving methadone therapy, it is im-
portant to know that oxygen therapy is administered 
in addition to CPAP. It is important to note that it 
corrects hypoxemia and does not cause respiratory 
depression, which can sometimes be observed. This 
is due to the fact that opioids stabilize breathing if the 
arousal threshold is low and the respiratory control-
ler gain is high, and associated with pain (24).
CONCLUSION
Our study found that the majority of drug addicts 
reported poor sleep quality. Although this study 
is based on self-reported data, it does show the po-
tential link between sleep problems and methadone 
therapy. 
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In the treatment of patients with sleep apnea 
as a result of opioids, in addition to the control of 
their psychiatrists, collaboration between special-
ists, monitoring of patients and a combination of 
different types of sleep apnea treatment is extreme-
ly important. 
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